



We are **LivaNova.**





Houston, Texas  
Cyberonics, Inc.

We are a new medical device company formed with the joining of two established market leaders.

We are pioneers and innovators in advanced devices for cardiac surgery, neuromodulation and cardiac rhythm management, with number-one and first-in-class market positions in a number of key areas of medical need.

We are at the intersection of advancing technology and transforming lives.

**We are LivaNova.**

---

## Letter from the Chairman

### Dear Shareholder,

On behalf of the Board of Directors, I am pleased to report that 2016, our first full year as LivaNova, has been a year with numerous accomplishments as well as some challenges. We have made great progress in many areas and created a solid platform for future growth.

I wish to express my thanks to André-Michel Ballester, who led our company during the merger process and the ensuing integration phase. We are confident that our new chief executive officer, Damien McDonald, and his leadership team will advance our strategy, which will maximize shareholder value and unlock the potential of this young company.

The Board assures the integrity of LivaNova's business operations through rigorous processes and controls. We believe that commercial success is directly related to operating


in a responsible way. It is probably not surprising, therefore, that compliance and risk management were important components of the Board's discussions during the year and will continue to be so going forward.

The board also understands and appreciates the importance of a workplace in which all of our employees feel valued, included and empowered. We recognize that each individual's unique experiences, perspectives and backgrounds are critical to creating the technologies upon which patients depend. As such, we are dedicated to fostering an environment that attracts more and more traditionally underrepresented talent to our global team.

Looking ahead, we see an environment filled with opportunities and of course, some associated risks. Through it all, we will pursue our fundamental commitment to innovation and growth, the

development and retention of the best talent, and the achievement of the highest quality in our products and manufacturing processes.

LivaNova is committed to improving the lives of patients and by doing so, creating long-term value for our shareholders. On behalf of LivaNova's Board of Directors and our many LivaNova colleagues, thank you for the trust you have placed in us to run this remarkable company. In everything we do, we strive to be worthy of that trust.



**Daniel J. Moore**  
Chairman of the Board, LivaNova Plc



---

Our people, our purpose and our solutions are transforming health and changing lives, worldwide.

Our journey is just beginning...

## Letter from the Chief Executive Officer

Dear Shareholder,

**I am excited and honored to lead LivaNova, where I have seen firsthand the passion and commitment to improve the lives of patients around the world.**

2016 was our first full year as a public company. It was a year focused on bringing together a dedicated workforce of more than 4,500 employees and creating a solid foundation from which to drive future growth. We made great strides by launching new products, capturing post-merger synergies and implementing major restructuring activities to improve profitability. We also focused investments in our highest growth drivers, eliminated duplication in our R&D portfolio, optimized inventory levels and enhanced our relationships with distributors in emerging markets. These initiatives helped us deliver multiple operational achievements.

Our Neuromodulation business franchise successfully rolled out our newest VNS Therapy® device, the AspireSR® pulse generator, to the epilepsy community. The market was quick to appreciate AspireSR's advanced technology, which detects heart rate changes associated with the onset of a seizure. As a result, the adoption rate was rapid and we experienced approximately seven percent new patient growth in 2016.

Also in 2016, our Cardiac Surgery business franchise received U.S. Food and Drug Administration approval of the Perceval™ aortic heart valve, the

only truly sutureless aortic heart valve. The valve was very well received in 2016, experiencing 50 percent year-over-year growth.

In our Cardiac Rhythm Management business franchise, our KORA 250™ full-body MRI compatible pacemaker continued to gain market share in Japan and our high-voltage PLATINIUM™ defibrillator experienced strong growth in Europe, significantly higher than market growth.

While the last 12 months presented us with many opportunities, we also faced certain challenges. One challenge relates to bacterial contamination in certain 3T Heater-Cooler™ devices. We recently announced a Device Remediation Plan to address this issue and will continue to work with interested parties to ensure access to this important device that enables lifesaving cardiac surgery.

Although we weren't able to grow our top line as fast as we would have liked, we were able to hit the high end of our adjusted earnings guidance, fully fund our exciting portfolio of equity investments and return \$50 million to shareholders in the form of a share buyback program.

In February 2017, we announced our intention to voluntarily delist from the London Stock Exchange. This was primarily due to the low trading volume on that exchange, and the fact that the vast majority of our shareholders trade on the NASDAQ market.

In conclusion, our primary goal over the last year was to ensure that we have in place a solid foundation from which to drive long-term growth,

a foundation comprised of a broad product portfolio, a global presence and a position of financial strength. This is a goal that we accomplished.

My first few months as Chief Executive Officer confirmed the nature and scale of the challenges we face, but also my view that within the organization, we have both the capabilities and skills necessary to achieve sustainable growth and to be a great place to work. Going forward, I see tremendous opportunities to maintain our strong leadership positions in cardiac surgery and neuromodulation by creating innovative new products designed to improve the lives of patients, and by investing wisely in growth, both organically and inorganically. We will continue to execute toward our strategy, expand our operating margins, and grow our revenues and earnings per share, all while improving the lives of patients and building long-term shareholder value.

We look forward to the future with confidence based on our people, processes and products. We are LivaNova.

Thank you,



**Damien McDonald**  
Chief Executive Officer, LivaNova Plc



## Leadership into Strength

We bring together world-class capabilities in three important areas of medical need: neuromodulation, cardiac rhythm management (CRM) and cardiac surgery.

### NEUROMODULATION

---

Pioneer in Vagus Nerve Stimulation (VNS) Therapy®

Leader in implantable devices for drug resistant epilepsy

Over 100,000 patients treated

### CRM

---

Innovative high-voltage product portfolio

Strong market position in Europe with PLATINIUM™

Robust presence in Japan with KORA 250™

### CARDIAC SURGERY

---

Number 1 in heart-lung machines and oxygenators

The market's only sutureless heart valve for aortic surgery

Approaching five decades of developing new technologies

---

### Market leadership joined by shared commitment to patients and healthcare providers

LivaNova is a market leader dedicated to delivering the highest quality products, making the greatest impact in patient's lives and creating a healthier tomorrow.

We are rooted in nearly five decades of experience and demonstrate a passion for innovation. Each of our business franchises offers advanced technologies and breakthrough treatments for the benefit of patients. We offer a comprehensive portfolio of cardiac surgery products. We treat cardiac rhythm disorders and heart failure, prevent seizures and treat depression. The devices we develop become meaningful solutions for patients, healthcare professionals and hospital systems.

## Strength into Growth

Health innovation that matters. This is our focus, the vision that guides our strategy to turn LivaNova's considerable strengths into positive impact, day by day, life by life.

### BROAD PORTFOLIO

Balance and breadth in key areas of medical need

### MARKET LEADERSHIP

60% of our sales in leading market share positions

### GLOBAL PRESENCE

Strong, balanced presence in U.S., Europe & Rest of World

### FINANCIAL STRENGTH

Low debt with flexibility to invest in growth over the long term

### A combination of strengths that positions LivaNova for powerful potential

In 2016, we created a solid foundation for future growth, merging our strengths and seizing opportunities. We are recognized as an innovator and leader in many of the markets we serve, bringing valuable techniques and solutions to our global customers. Based on our commitment to innovation and the strong demand for our products, we are positioned well for long-term growth.

We will maintain a focus on our growth drivers and exercise discipline in our internal and external investment decisions. Going forward, we expect gains from the continuing development of our current products and exciting launches of new products. We are creating a world-class company, demonstrating strength, leadership and ingenuity.

**We are creating technologies  
that transform lives.**

Epilepsy. Depression. Cardiopulmonary disease. These health issues affect the length and quality of life for millions worldwide. Each individual is more than a patient to us. Each is a story, a life spent striving for happiness, for fulfillment, for normalcy. These individuals inspire and drive us to do what we do, every day.





## I am Joe. I have epilepsy.

Everything in my life used to involve my epilepsy. The doctors tried all sorts of medications, but nothing really worked. I had a hard time in school and was afraid to do normal things like hang out with my friends, ride my bike or go anywhere in public. I was always afraid of what people would think if I had a seizure. When I was 13 years old, I received VNS Therapy® and all of that changed. For the first time in my life, I feel like my epilepsy doesn't hold me back. Now, I'm playing soccer, making new friends and feel like I can do anything. People don't realize how great it is to just fit in and feel normal.

A close-up portrait of a young woman with dark brown hair and bangs, looking directly at the camera with a neutral expression. She is wearing a dark plaid shirt and a gold necklace with a heart-shaped pendant. The background is a plain, light gray color.

## I am Nora. I have heart failure.

I always considered myself to be a healthy person, eating the right foods, doing yoga and rarely getting sick. But a year ago, I realized that I was feeling fatigued more often and had trouble catching my breath. I couldn't even climb stairs without taking a break. I was shocked when my doctor told me that my heart was desynchronized and I needed an implantable device to help improve its pumping capacity.

I thought I was much too young for a problem like that. I was nervous about the procedure and was expecting a long road to recovery, but I noticed a difference almost immediately afterward. Now, my energy levels are back, I feel much better and I'm excited to return to the things I love to do.

A close-up portrait of an elderly man with thinning grey hair, wearing black-rimmed glasses and a light-colored sweater over a blue and white checkered shirt. He has a gentle smile and is looking directly at the camera. The background is a plain, light grey.

## I am Giovanni. I have aortic stenosis.

I've led a long and happy life with many important milestones: meeting my beautiful wife, buying our first home, the birth of our children and retiring from a long and fruitful career. Getting an implant to replace a valve in my heart wasn't something I was looking forward to, but with the support of my family, the hospital and its staff the procedure went very well, and I no longer feel fatigued or lightheaded. Best of all, I never suffered any scarring or damage. These days, I still drive, help my "older" friends with their shopping every week and enjoy spoiling my grandchildren.

# Approaching Five Decades of Innovation...

LivaNova Products on Market as of 2016\*



AspireSR  
2016



PLATINIUM 4LV CRT-D  
2016



KORA 250  
2015



PLATINIUM  
2015



Memo 3D ReChord  
2014



Connect & HeartLink  
2013



Mitroflow Valsalva Conduit  
2013



Solo Smart  
2013



KORA 100  
2013



Inspire  
2012



Xtra 1  
2011



Aspire HC  
2011



PARADYM SonR  
2011



DemiPulse with Lead  
2009



Soprano Armonia  
2009



Perceval  
2007



REPLY DR  
2007



Memo 3D  
2006



S5 Heart-Lung Machine  
2005



Freedom Solo  
2004



Soprano  
2003



Carbomedics Carbo-Seal Valsal  
2003



SafeR  
2003



Pulse Model 102  
2002



Sovering Band  
2001



Sovering Miniband  
2001



3T Heater-Cooler  
1998



Carbomedics Annuloflo  
1998



Carbomedics Carbo-Seal  
1993



Carbomedics Top Hat  
1993



Bicarbon  
1990



Carbomedics Standard  
1986



Pyrolytic Carbon  
1969

PRODUCT KEY: ● Neuromodulation ● Cardiac Rhythm Management ● Cardiac Surgery

---

## LivanoVa Key Worldwide Locations

### Europe

- LivanoVa PLC (Headquarters)  
20 Eastbourne Terrace  
London, W2 6LG  
United Kingdom
- Clamart, France
- Milan, Italy
- Mirandola, Italy
- Saluggia, Italy
- Munich, Germany

### North America

- Houston, Texas
- Arvada, Colorado
- Vancouver, Canada

### Latin and South America

- San Paolo, Brazil
- Dominican Republic

### Asia

- Shanghai, China
- Tokyo, Japan



---

A presence in over 100 countries

More than 4,500 employees around the world

---

Any forward-looking statements are subject to risks and uncertainties such as those described in our periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.

# LivaNova

Health innovation that matters

## LivaNova PLC

20 Eastbourne Terrace  
London, W2 6LG  
United Kingdom

T +44 20 3325 0660

## LivaNova (USA)

100 Cyberonics Blvd.  
Houston, TX 77058  
USA

T +1 281 228 7200

[www.LivaNova.com](http://www.LivaNova.com)

